BridgeBio Pharma had its Relative Strength (RS) Rating upgraded from 77 to 84 Wednesday.
IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they begin their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
BridgeBio Pharma is now considered extended and out of buy range after clearing a 30.51 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% EPS growth in the latest quarterly report, while sales growth came in at -33%. Look for the next report on or around Feb. 20.
BridgeBio Pharma earns the No. 199 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
